Rafa Laboratories awarded $45M follow-on production agreement from U.S. DoD

Rafa Laboratories Ltd. was awarded a follow-on production agreement valued at over $45 million from the U.S. Department of Defense's JPEO-CBRND for the Midazolam Injection autoinjector (Advanced Anticonvulsant System). Deliveries began in December 2022.

“Rafa was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).”prnewswire.com

• 1 source
• prnewswire.comU.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 millionRafaFeb 23, 2023

Summarized from public sources; check the original articles before acting on it.